المؤلفون: Li, L, Mohanty, V, Dou, JZ, Huang, YF, Banerjee, PP, Miao, Q, Lohr, JG, Vijaykumar, T, Frede, J, Knoechel, B, Muniz-Feliciano, L, Laskowski, TJ, Liang, SH, Moyes, JS, Nandivada, V, Basar, R, Kaplan, M, Daher, M, Liu, EL, Li, Y, Acharya, S, Lin, PL, Shanley, M, Rafei, H, Marin, D, Mielke, S, Champlin, RE, Shpall, EJ, Chen, K, Rezvani, K

المصدر: Science advances. 9(30)

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:153504848

المؤلفون: Hernandez-Lopez P; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Vijaykumar T; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Anand P; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT., Frede J; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Knoechel B; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Lohr JG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.

المصدر: Blood advances [Blood Adv] 2024 Jun 25; Vol. 8 (12), pp. 3173-3185.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/metabolism , Multiple Myeloma*/pathology , Signal Transduction* , Tumor Microenvironment*, Humans ; Ligands ; Prognosis ; Disease Progression ; B-Lymphocytes/metabolism ; B-Lymphocytes/immunology ; Gene Expression Regulation, Neoplastic

المؤلفون: Im NG; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Institute for Translational Epigenetics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Guillaumet-Adkins A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Wal M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Rogers AJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Frede J; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Havig CC; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Yang J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Anand P; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Stegmann SK; Harvard Medical School, Boston, Massachusetts., Waldschmidt JM; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sotudeh N; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Niu L; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Voisine J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schweiger MR; Institute for Translational Epigenetics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Grassberger C; Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Lohr JG; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Knoechel B; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Division of Hematology/Oncology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts.

المصدر: Cancer immunology research [Cancer Immunol Res] 2022 Sep 01; Vol. 10 (9), pp. 1055-1068.

نوع المنشور: Editorial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, B-Cell*/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/metabolism, Antigens, CD19/immunology ; Germinal Center/immunology ; Humans ; Immunotherapy, Adoptive/methods ; Receptors, Antigen, T-Cell/immunology ; T-Lymphocytes/immunology

المؤلفون: Stover EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Oh C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Keskula P; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Tseng YY; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Adalsteinsson VA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ducar M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kryukov GV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Ha G; Public Health Sciences Division and Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Rosenberg M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Internal Medicine Program, Legacy Health, Portland, Oregon, USA., Freeman SS; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, USA., Wu X; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Takeda DY; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Pathology and Laboratory Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA., Wu CL; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Garraway LA; Genentech/Roche, San Francisco, California, USA., Boehm JS; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Huang FW; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.; Division of Hematology and Oncology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.

المصدر: The Prostate [Prostate] 2022 Apr; Vol. 82 (5), pp. 584-597. Date of Electronic Publication: 2022 Jan 27.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE

مواضيع طبية MeSH: Cell-Free Nucleic Acids* , Prostatic Neoplasms*/genetics, Cell Line ; Credentialing ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Male ; Mutation

المؤلفون: Waldschmidt JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yee AJ; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Vijaykumar T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pinto RA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Frede J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Anand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Bianchi G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Guo G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Potdar S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Seifer C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nair MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kokkalis A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kloeber JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shapiro S; Massachusetts General Hospital, Boston, MA, USA., Budano L; Massachusetts General Hospital, Boston, MA, USA., Mann M; Massachusetts General Hospital, Boston, MA, USA., Friedman R; Newton Wellesley Hospital, Newton, MA, USA., Lipe B; University of Rochester, Rochester, NY, USA., Campagnaro E; University of Michigan, Ann Arbor, MI, USA., O'Donnell EK; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Zhang CZ; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Raje NS; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Knoechel B; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. jensg_lohr@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. jensg_lohr@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jensg_lohr@dfci.harvard.edu.

المصدر: Leukemia [Leukemia] 2022 Apr; Vol. 36 (4), pp. 1078-1087. Date of Electronic Publication: 2022 Jan 13.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Cell-Free Nucleic Acids*/genetics , Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics, Humans ; Treatment Failure

المؤلفون: Waldschmidt JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kloeber JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Anand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Frede J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kokkalis A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dimitrova V; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Potdar S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Nair MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Vijaykumar T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Im NG; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Guillaumet-Adkins A; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chopra N; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Stuart H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Budano L; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Sotudeh N; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Guo G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Grassberger C; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Yee AJ; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Raje NS; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Knoechel B; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. jensg_lohr@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Dec 01; Vol. 27 (23), pp. 6432-6444. Date of Electronic Publication: 2021 Sep 13.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/drug therapy , Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics, Drug Resistance, Neoplasm ; Humans ; Mutation ; Neoplasm Recurrence, Local/drug therapy ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf ; Single-Cell Analysis

المؤلفون: Frede J; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Anand P; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sotudeh N; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Pinto RA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Nair MS; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA., Stuart H; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA., Yee AJ; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Vijaykumar T; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA., Waldschmidt JM; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Potdar S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kloeber JA; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA., Kokkalis A; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dimitrova V; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mann M; Massachusetts General Hospital, Boston, MA, USA., Laubach JP; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Richardson PG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Anderson KC; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Raje NS; Harvard Medical School, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Knoechel B; Harvard Medical School, Boston, MA, USA. birgit_knoechel@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. birgit_knoechel@dfci.harvard.edu.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. birgit_knoechel@dfci.harvard.edu., Lohr JG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA. jensg_lohr@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. jensg_lohr@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jensg_lohr@dfci.harvard.edu.

المصدر: Nature cell biology [Nat Cell Biol] 2021 Nov; Vol. 23 (11), pp. 1199-1211. Date of Electronic Publication: 2021 Oct 21.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Macmillan Magazines Ltd Country of Publication: England NLM ID: 100890575 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4679 (Electronic) Linking ISSN: 14657392 NLM ISO Abbreviation: Nat Cell Biol Subsets: MEDLINE

مواضيع طبية MeSH: Cellular Reprogramming* , Immunotherapy* , Transcription, Genetic*, Antineoplastic Agents/*pharmacology , Drug Resistance, Neoplasm/*genetics , Multiple Myeloma/*drug therapy , Receptors, CXCR4/*antagonists & inhibitors, Aged ; Aged, 80 and over ; Cell Line, Tumor ; Cell Lineage ; Cell Plasticity ; Female ; Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Multiple Myeloma/genetics ; Multiple Myeloma/immunology ; Multiple Myeloma/metabolism ; Receptors, CXCR4/genetics ; Receptors, CXCR4/metabolism ; Transcriptome

المؤلفون: Hanna GJ; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA. Electronic address: glenn_hanna@dfci.harvard.edu., ONeill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, USA., Cutler JM; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Flynn M; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Vijaykumar T; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Clark JR; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Wirth LJ; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Lorch JH; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Park JC; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Mito JK; Department of Pathology, Brigham & Women's Hospital, Boston, USA., Lohr JG; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Kaufman J; Adenoid Cystic Carcinoma Research Foundation, USA., Burr NS; Adenoid Cystic Carcinoma Research Foundation, USA., Zon LI; Department of Stem Cell and Regenerative Biology, Boston Children's Hospital and Harvard Medical School, Boston, USA., Haddad RI; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA.

المصدر: Oral oncology [Oral Oncol] 2021 Aug; Vol. 119, pp. 105366. Date of Electronic Publication: 2021 Jun 03.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Adenoid Cystic*/drug therapy, Tretinoin/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Phosphatidylinositol 3-Kinases ; Treatment Outcome

المؤلفون: Anand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Guillaumet-Adkins A; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Dimitrova V; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Yun H; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Drier Y; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Sotudeh N; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Rogers A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Ouseph MM; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Nair M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Potdar S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Isenhart R; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Kloeber JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Vijaykumar T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Niu L; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Vincent T; Children's Hospital of Philadelphia, Philadelphia, PA; and., Guo G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Frede J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Harris MH; Department of Pathology and., Place AE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Department of Medicine, Boston Children's Hospital, MA., Silverman LB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Department of Medicine, Boston Children's Hospital, MA., Teachey DT; Children's Hospital of Philadelphia, Philadelphia, PA; and., Lane AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Aster JC; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Bernstein BE; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Knoechel B; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology/Oncology, Department of Medicine, Boston Children's Hospital, MA.

المصدر: Blood [Blood] 2021 May 06; Vol. 137 (18), pp. 2463-2480.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Carcinogenesis* , Gene Expression Regulation, Leukemic* , Immune Evasion*, Galectins/*metabolism , Neoplastic Stem Cells/*pathology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*pathology , Single-Cell Analysis/*methods, Adolescent ; Adult ; Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Child ; Child, Preschool ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Galectins/genetics ; Hepatitis A Virus Cellular Receptor 2/genetics ; Hepatitis A Virus Cellular Receptor 2/metabolism ; Humans ; Infant ; Male ; Middle Aged ; Mutation ; Neoplastic Stem Cells/immunology ; Neoplastic Stem Cells/metabolism ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Prognosis ; RNA-Seq/methods ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays ; Young Adult

المؤلفون: Waldschmidt JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Vijaykumar T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Knoechel B; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: jensg_lohr@dfci.harvard.edu.

المصدر: Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2020 Mar; Vol. 33 (1), pp. 101146. Date of Electronic Publication: 2020 Jan 14.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101120659 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1924 (Electronic) Linking ISSN: 15216926 NLM ISO Abbreviation: Best Pract Res Clin Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Genome, Human* , Mutation*, Biomarkers, Tumor/*genetics , Circulating Tumor DNA/*genetics , Multiple Myeloma/*diagnosis , Multiple Myeloma/*genetics, Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/blood ; Circulating Tumor DNA/blood ; GTP Phosphohydrolases/blood ; GTP Phosphohydrolases/genetics ; Gene Expression Profiling ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Liquid Biopsy/methods ; Membrane Proteins/blood ; Membrane Proteins/genetics ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Neoplasm, Residual ; Plasma Cells/drug effects ; Plasma Cells/metabolism ; Plasma Cells/pathology ; Proto-Oncogene Proteins B-raf/blood ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/blood ; Proto-Oncogene Proteins p21(ras)/genetics ; Recurrence ; Tumor Suppressor Protein p53/blood ; Tumor Suppressor Protein p53/genetics